Invenra Inc. announced a strategic collaboration with Catalent. The collaboration will harness the combined expertise and proprietary technologies of Invenra and Catalent to co-d discover novel bispecific antibody-drug conjugates. Both companies share a commitment to developing novel therapeutic solutions with the potential to make a meaningful impact in the lives of patients.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
55.85 USD | -0.80% | -0.32% | +24.30% |
Apr. 12 | Zacks Investment Research Downgrades Catalent to Underperform From Neutral, Price Target is $48 | MT |
Apr. 08 | Sector Update: Health Care Stocks Decline Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.30% | 10.19B | |
+34.00% | 664B | |
+29.29% | 567B | |
-7.75% | 354B | |
+18.53% | 330B | |
+4.95% | 286B | |
+13.79% | 234B | |
+4.93% | 199B | |
-9.78% | 196B | |
-4.89% | 148B |
- Stock Market
- Equities
- CTLT Stock
- News Catalent, Inc.
- Invenra Inc. Announces Strategic Collaboration with Catalent to Co-Discover Novel Bispecific ADCs